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Abstract:
Objective: To determine whether patients newly prescribed antihypertensive
therapy after the JNC 8 update were treated to a relaxed SBP goal compared to
patients treated before the update.
Methods: Retrospective cohort study approved by Colorado Multiple Institutional
Review Board. Patients aged 60-79 years, without diabetes or chronic kidney
disease, newly treated for hypertension at a University of Colorado primary care
clinic were included. Mean first-achieved and last-stable SBP of patients newly
prescribed antihypertensive medications from January 1, 2012 to December 31,
2013 (before cohort) were compared to patients newly prescribed
antihypertensive therapy from January 1, 2014 to October 1, 2015 (after cohort).
Mean number of antihypertensive medications at first-achieved SBP, time to firstachieved SBP, and class of initial antihypertensive medications were also
evaluated.
Results: A total of 128 patients were included, 64 patients in each cohort. The
co-primary outcome of first-achieved mean SBP did not differ between groups
(131.3 vs 130.2 mm Hg; p=0.65). Last-stable mean SBP values were also similar
between groups (130.2 vs 129.5 mm Hg; p=0.74). Within both cohorts,
angiotensin converting enzyme inhibitors were the most frequently initiated
antihypertensive agents (43.8% vs 48.4%; p=0.72).
Conclusions: Our findings suggest that the JNC 8 recommendations did not
alter SBP goals among patients aged 60-79 years newly treated for hypertension
at University of Colorado primary care clinics.
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Introduction:
Hypertension, a major modifiable risk factor for cardiovascular disease (CVD),
stroke, and chronic kidney disease (CKD), affects nearly one-third of U.S. adults
aged 20 years and older (Mozaffarian et al. 2016). The prevalence of
hypertension increases with age, with 65% of patients aged ≥ 60 years meeting
diagnostic criteria for hypertension (Mozaffarian et al. 2016). Although a greater
percentage of patients aged ≥ 60 years have controlled hypertension (blood
pressure < 140/90 mm Hg) compared to younger patients, the number of older
patients with hypertension that have controlled blood pressure (BP) remains
suboptimal at 54.1% (Mozaffarian et al. 2016).
In 2014, two U.S. hypertension guidelines were published. The American Society
of Hypertension and the International Society of Hypertension (ASH/ISH), and a
report from the panel members appointed to the Eighth Joint National Committee
(JNC 8)(Weber et al. 2014; James et al. 2014). Both of these guidance
documents provided recommendations on BP thresholds for initiating
antihypertensive treatment, preferred initial pharmacologic options, and goal BP
values in specific patient populations (Weber et al. 2014);(James et al. 2014).
While both recommended a relaxed systolic blood pressure (SBP) goal of < 150
mm Hg in elderly patients, they recommended different ages at which the SBP
goal should be relaxed. The updated JNC 8 report recommended a SBP target of
< 150 mm Hg in adults aged ≥ 60 years, without diabetes or CKD. This
recommendation was given a Grade A recommendation, using a grading system
developed by the National Heart, Lung, and Blood Institute’s Evidence-Based
Methodology Lead (James et al. 2014). Although graded as a strong
recommendation, the age at which to relax the SBP goal differs from several
other hypertension guidelines that recommend relaxing the SBP goal to < 150
mm Hg for patients aged ≥ 80 years (Daskalopoulou et al. 2015; Mancia et al.
2013; Weber et al. 2014).
Several experts, including a minority of JNC 8 panel members, expressed
concern that evidence supporting the relaxed SBP target is insufficient (Krakoff
et al. 2014);(Wright et al. 2014). Moreover, the relaxed SBP target may lead to
under treatment of high-risk patients. Additionally, several registry analyses
have compared the proportion of patients meeting blood pressure targets as
recommended by JNC 8 and previous JNC 7 recommendations. These
analyses found that 6.8-11.6% of adults aged ≥ 60 years without diabetes or
CKD would be reclassified as meeting blood pressure targets by relaxing the
SBP goal of < 150 mm Hg (Borden et al. 2014; Navar-Boggan et al. 2014;
Miedema et al. 2015). Given the controversy surrounding the relaxed SBP goal
in patients aged ≥ 60 years, and several other hypertension guidelines
recommending a relaxed SBP goal starting at age 80, the objective of this study
was to determine whether patients newly prescribed antihypertensive therapy
after the JNC 8 report were treated to a relaxed SBP compared to patients
newly treated before the JNC 8 report.
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Methods:
Study design – This retrospective cohort study compared the SBP values of
patients newly prescribed antihypertensive therapy for a new diagnosis of
hypertension in one of seven University of Colorado Health (UCH) primary care
clinics. These seven clinics included family medicine and internal medicine
clinics, three of which are medical resident training sites, and most have clinical
pharmacy services. Two primary endpoints were used as surrogate markers of
SBP goal between cohorts; mean first-achieved SBP and mean last-stable SBP.
First-achieved SBP was defined as the SBP value, obtained during a primary
care clinic visit in which hypertension disease state was assessed after
prescribing antihypertensive therapy, and no modifications were made to
antihypertensive treatment plan. Last-stable SBP was defined as the most recent
in-office SBP reading, where hypertension was assessed, and no modifications
were made to antihypertensive treatment plan. SBP values recorded during clinic
visits where hypertension was not assessed (i.e. acute illness visits) were not
included. Secondary endpoints included time to first-achieved SBP, number of
antihypertensive medications to reach first-achieved SBP, class of
antihypertensive medication initiated, and number of medications at last-stable
SBP.
Patient population – Patients aged 60 to 79 years with newly prescribed
treatment for hypertension during the study period of January 1, 2012 to October
1, 2015 were eligible for this study. Additional inclusion criteria included a new
diagnosis of hypertension (ICD-9 code 401.x) and at least one additional visit to
the primary care clinic after being prescribed antihypertensive therapy, where
hypertension was assessed and no changes were made to patients’
antihypertensive regimen. Exclusion criteria included a diagnosis of diabetes
mellitus (ICD-9 code 250.x), CKD (ICD-9 code 585.x), or kidney transplant (ICD9 code V42.0). Patients receiving antihypertensive therapy for indications other
than hypertension (i.e. atrial fibrillation, benign prostate hypertrophy, edema)
prior to new hypertension diagnosis were also excluded. A list of potentially
eligible patients was generated from our electronic health record (EHR) based on
study criteria.
Potentially eligible patients were assigned to one of two cohorts (Figure 1). The
before JNC 8 group consisted of patients newly prescribed antihypertensive
therapy during the period of January 1, 2012 to December 31, 2013, while
patients newly prescribed antihypertensive therapy during the period of January
1, 2014 to October 1, 2015 comprised the after JNC 8 group. The cohort time
periods were chosen to provide an approximately equal time frame, and to allow
time for the JNC 8 report to be disseminated to primary care providers. The
online JNC 8 report was first available beginning December 18, 2013. January 1,
2014 was chosen as the initial date for the after JNC cohort, believing that
enough time had passed since online publication for providers to be aware of the
JNC 8 recommendations.
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Patients in each cohort were randomly sorted, then EHRs were manually
reviewed to ascertain if patient met criteria. The following patient data were
extracted and collected for analysis: age, gender, ethnicity/race, current tobacco
use, date of newly prescribed antihypertensive agent, initial in-clinic SBP,
antihypertensive agent prescribed, unique number of antihypertensive
medications at primary care visits, dates at which BP is assessed in clinic visit
and no changes made to antihypertensive regimen, and SBP on eligible dates.
Statistical analysis– Primary and secondary continuous endpoints were
compared between cohorts using unpaired t-test with Microsoft Excel.
Categorical data were analyzed using two-tailed chi-square or Fisher’s exact
tests,
calculated
with
GraphPad
Software
(http://graphpad.com/quickcalcs/contingency2/). A sample size calculation
(http://clincalc.com/Stats/SampleSize.aspx) determined that a total of 128
patients (64 per group) would be necessary to provide 80% power (α=0.05) to
detect a clinically significant 6 mm Hg SBP difference (standard deviation 12 mm
Hg) between groups, similar to the BP parameters reported in the VALISH study
(Ogihara et al. 2010). Patient EHRs were reviewed until a total of 64 patients
meeting inclusion criteria in each cohort were identified. This study received
expedited approval by Colorado Multiple Institutional Review Board.
Results – Of the 671 patients reviewed, 128 patients met study criteria (Figure
2). Most patients (67.2%) were excluded for having a previous diagnosis of
hypertension at their initial visit when establishing care at one of the primary care
clinics. Baseline characteristics were similar between groups (Table 1), including
a majority of non-Hispanic white patients, mean age of 66 years, and low
prevalence of tobacco use. Patients with known CVD were excluded from this
study population, as they would have likely been receiving one or more
antihypertensive agents as recommended by CVD guidelines (Fihn et al. 2012).
Patients in both cohorts had a similar initial SBP, which trended higher in the
after JNC 8 group, but was not statistically different (153.7 mm Hg vs 157.7 mm
Hg; p = 0.07).
The co-primary endpoint (Table 2) of mean first-achieved SBP did not differ
significantly between groups (131.3 vs 130.2 mm Hg; p = 0.65). Additionally, no
statistical difference in the second co-primary endpoint of mean last-stable SBP
(Table 2) was found between study groups (130.2 vs 129.5 mm Hg; p = 0.74).
Table 3 reports the frequencies of each antihypertensive agent prescribed as
initial therapy. Angiotensin converting enzyme inhibitors (ACE-I) were the most
frequently prescribed initial antihypertensive agent in both the before and after
cohorts, 43.8% vs 48.4%, respectively (p = 0.72). Calcium channel blockers or
thiazides were initiated as initial antihypertensive therapy in non-Hispanic black
patients at a similar frequency in both the before and after cohorts, 57.1% vs
60.0%, respectively (p = 1.0).
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DISCUSSION:
This retrospective study of patients aged 60-79 years newly prescribed
antihypertensive treatment found no difference in our primary endpoints of firstachieved SBP and last-stable SBP among patients treated before and after the
JNC 8 report. Both cohorts reached a mean SBP of approximately 130 mm Hg
with minimal antihypertensive medications (mean 1.2 antihypertensive agents).
This suggested a high degree of goal attainment, regardless of the BP goal value
selected. Both cohorts demonstrated a considerable reduction in SBP (-22.4 mm
Hg in the before JNC 8 cohort and -27.5 mm Hg in the after JNC 8 cohort), easily
meeting SBP goal of < 140 mm Hg and < 150 mm Hg. The JNC 8 report
recommended that antihypertensive treatment need not be modified if patients
achieve a SBP below < 140 mm Hg and have no adverse effects associated with
antihypertensive treatment (Grade E - expert opinion) (James et al. 2014). Thus,
in patients with a SBP goal of < 150 mm Hg who achieved a SBP less than 140
mm Hg, modification of antihypertensive therapy would not be necessary unless
they experienced adverse effects. Patients in both cohorts achieved and
maintained well-controlled SBP values that did not appear to be associated with
adverse effects that would require modifications to antihypertensive therapy.
Our results suggest that patients included in our study may have been treated to
a more intense SBP goal than recommended by the JNC 8 report. Recently, the
Systolic Blood Pressure Intervention Trial (SPRINT) found that targeting a more
intensive SBP goal (< 120 mm Hg) compared to standard SBP (< 140 mm Hg) in
patients with CVD risk factors resulted in a significantly lower rate of major CVD
events and all-cause mortality (Anon 2015). Our study population did differ from
patients included in SPRINT in many ways. First, our study population did not
include patients with CKD and known CVD, while the SPRINT trial included a
high percentage of patients with CKD (28%) and known CVD (20%). Additionally,
most patients in the SPRINT trial (> 90%) were receiving antihypertensive
treatment at baseline with a mean SBP of 140 mm Hg. Our patient population
included patients with newly diagnosed, untreated hypertension with low CVD
risk. Recently, a subgroup analysis of patients aged ≥ 75 years from the SPRINT
trial reported a >30% reduction in all-cause mortality and the primary composite
endpoint of major cardiovascular events in the group treated to intensive SBP
goal < 120 mm Hg compared to SBP < 140 mm Hg (Williamson et al. 2016).
Given evidence from the SPRINT trials, the JNC 8 recommendation to target
SBP < 150 mm Hg seems inappropriate.
A previous study conducted at the same academic health system found no
difference in mean BP and number of antihypertensive agents between a similar
cohort of patients aged 60-79 years, treated for hypertension 1-year before and
1-year after the JNC 8 report (Fixen et al. 2016). Of note, patients in the previous
study had an existing diagnosis of hypertension and were currently receiving
antihypertensive therapy. Additionally, most patients (86%) were included in both
the before and after cohort. Our current study excluded patients with a prior
diagnosis of hypertension and those currently receiving antihypertensive
medications. Additionally, our study design did not permit patients to be included
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in both the before and after cohorts. Therefore, our results are a better measure
of how the JNC 8 report has influenced primary care providers in treating
hypertension in an elderly population.
One possible explanation for the substantial reduction in SBP seen in both
cohorts may be due to the health status of the patients studied. Patients in our
study had a mean age of 66 years, which is younger than patients studied in
previous isolated systolic hypertension trials (mean age range 70-84 years)
(Anon 1991; Staessen et al. 1997; Beckett et al. 2008; JATOS Study Group
2008; Ogihara et al. 2010). Our patients had few comorbidities as our exclusion
criteria did not include patients with diabetes or CKD, and patients with known
CVD receiving recommended medical therapy would have been excluded. Of the
five trials reviewed by the JNC 8 members that included patients aged ≥ 60
years, four trials included patients (range 7% to 13.7%) with diabetes mellitus
(Anon 1991; Beckett et al. 2008; JATOS Study Group 2008; Ogihara et al. 2010).
The Syst-Eur trial did not report the percentage of patients with diabetes, but did
report that nearly 30% of included patients had a history of cardiovascular
complications at baseline (Staessen et al. 1997).
It is possible that a portion of our study patients may not have had true
hypertension, but instead presented with white-coat hypertension (WCH). It is
estimated that up to 30% of patients with elevated in-clinic BP values may have
WCH (Siu & U.S. Preventive Services Task Force 2015). In 2015, the U.S.
Preventive Services Task Force released recommendations to confirm the
diagnosis of hypertension with the use of out-of-clinic BP values (Siu & U.S.
Preventive Services Task Force 2015). A recent subgroup analysis examined the
prevalence of WCH in patients with in-clinic HTN (BP ≥ 140/90 mm Hg) who also
underwent 24-hour ambulatory blood pressure monitoring (ABPM) (Tanner et al.
2016). In the subset of patients without diabetes or CKD, patients aged ≥ 60
years had a significantly greater in office SBP compared to patients aged < 60
years (149.9 mm Hg vs 140.9 mm Hg, respectively; p < 0.001), but similar SBP
measured by ABPM (134.8 mm Hg vs 132.2 mm Hg; p = 0.22). The prevalence
of patients in our study with WHC cannot be determined given the retrospective
study design.
Both ASH/ISH guidelines and the JNC 8 report recommend one of four classes
of antihypertensive agents as initial therapy in non-Hispanic black patients. Our
study found that ACE-I were the most frequently prescribed initial agent in both
cohorts and also noted several other trends in prescribed initial antihypertensive
therapy. First, the frequency of beta-blockers as initial therapy in the before JNC
8 cohort trended down in the after JNC 8 cohort (6.3% vs 3.1%; p=0.68), which is
in line with recommendations against the use of beta-blocking agents as first-line
antihypertensive agents.(Weber et al. 2014; James et al. 2014) Second, we
found an increased frequency of angiotensin receptor blockers (ARBs) use as
initial therapy from 7.8% in the before cohort to 10.9% in the after cohort
(p=0.76). This trend may be explained by the fact that several ARBs became
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available as generic products after the release of JNC 8. Due to ASH/ISH and
JNC 8 recommendations specifying initial antihypertensive therapy in nonHispanic black patients, a pre-specified subgroup analysis was conducted to
determine if more non-Hispanic black patients in the after JNC 8 cohort were
initially prescribed a calcium channel blocker (CCB) or thiazide compared to nonHispanic black patients in the before JNC 8 cohort. A total of 12 non-Hispanic
black patients were included in the patient sample, (seven in the before cohort
and five in the after cohort) with no statistical difference between groups. A future
study including only non-Hispanic black patients may be useful to determine if
initial antihypertensive therapy follows the recommendations from both U.S.
hypertension guidelines (Weber et al. 2014; James et al. 2014).
There are several limitations of this study, most notably our retrospective design.
First, medication adherence could not be assessed due to our study design,
which may have falsely increased our secondary endpoint of time to firstachieved SBP. In a study assessing adherence to antihypertensive medications
among patients newly treated for hypertension, less than 10% of subjects had an
adherence rate ≥ 80% (portion of days covered) at 6 months (Mazzaglia et al.
2009). Secondly, we can not ensure that BP was measured using the
recommended technique described by hypertension guidelines (Weber et al.
2014). A third limitation of this study is our use of surrogate endpoints to evaluate
SBP goals, since BP goals were not consistently documented in the EHR.
Although we limited our assessment to only SBP values during clinic visits
assessing patients’ hypertension disease state, patients who achieved a SBP
below their goal value without adverse effects would be recommended to
continue current antihypertensive therapy, based upon the JNC 8 corollary
recommendation (James et al. 2014). Lastly, our study included a limited number
of primary care clinics, all of which are affiliated with a single academic health
system and have clinical pharmacy services available. Several clinics have
collaborative drug therapy management (CDTM) protocols, which allow
pharmacists to manage and modify patients’ antihypertensive therapy in
collaboration with primary care providers. Whether the availability of clinical
pharmacy services influenced the SBP goal of patients included in this study
cannot be determined. Future studies comparing the achieved SBP values for
patients initiating antihypertensive treatment in primary clinics affiliated with an
academic health center compared to primary care clinics not affiliated with
academic health centers may be of value.

Conclusion
Our findings did not identify a change in overall intensity of BP lowering among
patients with newly diagnosed hypertension. Our findings were limited to patients
aged 60 to 79 years, without CKD or diabetes, receiving care from primary care
providers of an academic health system. Overall, treatment of this population
does not appear to have been negatively influenced by the JNC 8
recommendations to relax the SBP goal among these patients.
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Table 1: Patient demographics of before and after cohorts at baseline
Before JNC 8
After JNC 8
Characteristic
P value
(n=64)
(n=64)
Mean age in years (SD)
65.8 (4.9)
66.2 (4.6)
0.33
Female sex (%)
64.1
64.1
1.00
Race/Ethnic group (%)
???
Non-Hispanic white
79.7
78.1
Non-Hispanic black
10.9
7.8
Hispanic
3.1
4.7
Other
6.3
9.4
Current Tobacco use (%)
17.2
9.4
0.30
Initial mean SBP in mm Hg
153.7 (11.0)
157.7 (13.3)
0.07
(SD)
Initial mean DBP in mm Hg
87.0 (9.5)
89.2 (8.6)
0.16
(SD)
DBP= diastolic blood pressure; JNC 8= Eighth Joint National Committee;
SBP= systolic blood pressure; SD = standard deviation.

Systolic blood pressure in patients aged 60-79 years before and after JNC 8

11

Table 2: Results of primary endpoints
Before JNC 8
(n=64)
First-achieved SBP (mm Hg)
131.3 ± 13.6

After JNC 8
(n=64)
130.2 ± 11.7

P value
0.65

First-achieved DBP (mm Hg)

76.6 ± 10.2

79.0 ± 8.4

0.15

Last-stable SBP (mm Hg)

130.2 ± 12.2

129.5 ± 11.8

0.74

Last-stable DBP (mm Hg)
78.1 ± 7.2
77.2 ± 8.6
0.53
*Plus-minus values are mean ± standard deviation; DBP= diastolic blood
pressure; JNC 8= Eighth Joint National Committee; SBP= systolic blood
pressure.
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Table 3: Results of secondary endpoints
Before
After
JNC 8
JNC 8
(n=64)
(n=64)
Time to first-achieved
83.7
77.1
SBP (days)
Medications to reach
first-achieved SBP
1.23
1.17
(no.)
Medications at last1.16
1.25
stable SBP (no.)

P value
0.65
0.41
0.33

Class of medication initiated (%)
0.50
ACE-I
43.8
48.4
0.72
ARB
7.8
10.9
0.76
CCB
12.5
10.9
1.00
Thiazide
26.6
15.6
0.19
Beta-blocker
6.2
3.1
0.68
Aldosterone
1.00
0.00
1.6
antagonist
Combination
medication
ACE-I/HCTZ
3.1
7.8
0.21
ARB/HCTZ
0.0
1.6
1.00
ACE-I= angiotensin converting enzyme inhibitor; ARB=
angiotensin receptor blocker; CCB= calcium channel
blocker; HCTZ= hydrochlorothiazide; JNC 8= Eighth Joint
National Committee; No.= number; SBP= systolic blood
pressure.
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Figure 1: Study cohorts by date
Patients aged 60-79 years, newly treated for hypertension
at 1 of 7 UCH primary care clinics

Before JNC 8

After JNC 8

January 1, 2012 December 31, 2013

January 1, 2014 October 1, 2015

JNC 8 (online) December 18, 2013
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Figure 2: Patients screened and included in analysis.
Total Patients Screened
N= 671

Patients Excluded
N= 543
365
86
41
39

Eligible Patients Included in
Analysis
N = 128

Before JNC 8
N = 64

12

Had diagnosis of HTN
Taking ≥1 antihypertensive
medication at diagnosis
Not treated with medication for HTN
Medication not prescribed by primary
provider
No follow-up visit

After JNC 8
N = 64

HTN= hypertension; JNC 8= Eighth Joint National Committee
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